T. Rowe Price Investment Management, Inc. Erasca, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 16,710,347 shares of ERAS stock, worth $24.4 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
16,710,347
Previous 16,830,856
0.72%
Holding current value
$24.4 Million
Previous $45.9 Million
8.72%
% of portfolio
0.03%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
227MCall Options Held
10.9KPut Options Held
65.1K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$28.3 Million2.92% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$23.7 Million6.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$18.5 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$18.3 Million4.12% of portfolio
-
Suvretta Capital Management, LLC New York, NY12.3MShares$18 Million1.29% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $178M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...